Table 2.
Parameter | Case 1 | Case 2 | ||
---|---|---|---|---|
Neonatal details | ||||
Maturity | Term | Term | ||
Mode of delivery | Vaginal delivery | Cesarean delivery (abruption) | ||
Infection-delivery interval (day) | 1 | 4 | ||
Birth weight (kg) | 2.6 | 2.25 | ||
Sex | Female | Male | ||
Apgar score at 5 min | 8 | 8 | ||
Positive nasopharyngeal RT-PCR | 24 hours | 4th day | ||
Negative nasopharyngeal RT-PCR | 4th ,7th postnatal day | 7th, 10th postnatal day | ||
Biological samples | Not collected | Collected | ||
Vaginal fluid | Not done | Negative | ||
Amniotic fluid | Not done | Negative | ||
Placental membrane swab | Not done | Negative | ||
Cord blood | Not done | Negative | ||
Breast milk for RT-PCR | Negative | Negative | ||
Roomed in, breast fed | Yes | No | ||
Contact with mother | Yes | No, separated immediately from mother and kept in NICU | ||
Symptoms in neonate | Asymptomatic | Asymptomatic | ||
Investigations of neonate day 1 | ||||
Hemoglobin (gm/dL) | 16.4 | 18.9 | ||
Total leucocyte count (cells/mm3) | 17,600 | 18,500 | ||
Differential leucocyte count (%) | P67, L26, E3, M4 | P71, L20, E6, M3 | ||
Platelet count (lac/mm3) | 1.84 | 1.93 | ||
Bilirubin (mg/dL) | 0.8 | 1.1 | ||
Alanine aminotransferase (IU/L) | 19 | 24 | ||
Aspartate aminotransferase (IU/L) | 48 | 62 | ||
Urea (mg/dL) | 16.4 | 15.2 | ||
Creatinine (mg/dL) | 0.89 | 1.0 | ||
Hospital stay (day) | 7 | 10 | ||
Maternal characteristics | ||||
COVID status at admission | Suspect (from hotspot/cluster area) | Positive | ||
Age (yr) | 29 | 26 | ||
Parity | G5P4L4 (previous normal delivery) | G2P1L1 (previous cesarean) | ||
Symptoms in mother | Asymptomatic | Asymptomatic | ||
GA on admission | 38 weeks 5 days | 37 weeks 5 days | ||
Pregnancy associated complications | No | Antepartum hemorrhage (abruption) | ||
Comorbidity | No | No |
COVID-19, coronavirus disease 2019; RT-PCR, reverse transcription-polymerase chain reaction; NICU, neonatal intensive care unit; GA, gestational age.